ALK Positive Grants Support Dr. Alice Shaw’s Pioneering ALK-Positive Lung Cancer Research

ALK Positive is proud to support Dr. Alice Shaw’s pre-clinical research advancing the understanding of ALK-positive lung cancer. Her work focuses on uncovering biological mechanisms that drive treatment resistance, with the goal of informing future therapeutic strategies and improving long-term outcomes for patients. Through this partnership, ALK Positive is investing in science that accelerates progress…

We’re proud to share that ALK Positive’s generous grant to Dr. Alice Shaw, MD, PhD at Dana-Farber Cancer Institute was recently featured in Dana-Farber Impact Magazine. Impact Magazine

This funding supports Dr. Shaw’s groundbreaking research on methylthioadenosine phosphorylase (MTAP) loss in ALK-positive lung cancer — a project poised to deepen scientific understanding and inform new approaches to treatment for people living with this disease.

Dr. Shaw is a global leader in ALK-positive lung cancer research and care, and her work continues to move the field forward. ALK Positive’s grant helps accelerate this vital investigation at a critical time, reflecting our commitment to patient-driven research that directly impacts the ALK+ community.

We extend gratitude to our donors and partners whose support makes funding research like this possible. By investing in science today, we help build a future with better treatments — and more time — for people living with ALK-positive cancer.

📖 Read the full Impact Magazine piece: https://danafarberimpact.org/2025/11/alk-positive/

Releated Posts